Marta P. D.
- Country
- Spain
- Department
- Hematology
Research Overview
- A multi-center randomized, double blinded phase IIb trial evaluating oral pooled fecal microbiotherapy MaaT033 to prevent allogeneic hematopoietic cell transplantation complications
- Phase III Randomized, Double-Blind, Placebo-Controlled Study of Mocravimod as Adjunctive and Maintenance Therapy in Acute Myeloid Leukemia Undergoing Allo-HCT
- Evaluation of MaaT013 Efficacy in Gastrointestinal Acute Graft-Versus-Host Disease Refractory to Ruxolitinib: A Phase III Multicenter Open-Label Trial
Data & Insights
Has run more than one trial at 38 of 100 partner sites.
Specializations
Transplant Medicine
The investigator specializes in allogeneic hematopoietic cell transplantation (allo-HCT) and its complications, with particular focus on therapeutic approaches for transplant-related challenges.
- Post-transplant care management
- Maintenance therapy development
- Transplant outcome optimization
Immunological Disorders
Primary expertise centers on treating graft-versus-host disease (GvHD), particularly focusing on gastrointestinal manifestations and innovative therapeutic approaches for treatment-resistant cases.
- Gastrointestinal GvHD management
- Refractory condition treatment
- Novel therapeutic interventions
Hematologic Conditions
The investigator focuses on acute myeloid leukemia (AML) treatment pathways, specifically exploring adjunctive therapies and treatment strategies to improve patient outcomes following transplantation.
- AML treatment optimization
- Post-transplant care protocols
- Therapeutic resistance management
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.